Semaglutide Medicinal

Semaglutide Dosing in the Clinical Literature

Semaglutide dosing: how clinical trials escalated and maintained

Semaglutide dosing in clinical trials follows a structured escalation protocol designed to minimize gastrointestinal adverse events — the most common semaglutide finding across all Phase 3 programs. The dose-escalation schedule developed across the STEP and SUSTAIN trials begins at the lowest effective dose and advances in 4-week increments to allow GI tolerance to develop.

This page summarizes only the doses studied in published clinical trials. All doses described here are from trial protocols and FDA-approved labeling, documented in the peer-reviewed literature. This is not a clinical recommendation, and no dose on this page should be interpreted as guidance for any individual.

Subcutaneous Escalation Protocol in STEP Trials

The STEP trials used a 16-week escalation schedule to reach the 2.4 mg maintenance dose:

  • Weeks 1-4: 0.25 mg SC once weekly
  • Weeks 5-8: 0.5 mg SC once weekly
  • Weeks 9-12: 1.0 mg SC once weekly
  • Weeks 13-16: 1.7 mg SC once weekly
  • Week 17 onward: 2.4 mg SC once weekly (maintenance)

This schedule is the same protocol used in STEP-1 through STEP-5 [1][6]. The SUSTAIN trials for type 2 diabetes used a shorter escalation reaching 0.5 mg or 1.0 mg maintenance, depending on the specific trial arm. SUSTAIN-1 used 0.5 mg and 1.0 mg weekly arms [7].

The escalation structure directly addresses GI tolerability. GI adverse events (nausea, vomiting, diarrhea, constipation) are most frequent during dose-escalation steps and attenuate at stable maintenance doses [17]. Participants who are not tolerating a dose step may maintain the lower dose for an additional 4 weeks per trial protocols — a protocol feature reflected in the FDA-approved labeling.

The semaglutide dosing schedule page provides the complete escalation framework. All doses here describe what was administered in published clinical trials.

Semaglutide Half-Life and Pharmacokinetics

Semaglutide's plasma half-life of approximately 145-168 hours is the pharmacokinetic feature that enables once-weekly subcutaneous dosing and distinguishes it from shorter-acting GLP-1 agonists. The half-life is achieved through two molecular modifications: the C-18 fatty diacid side chain that binds serum albumin (>99% albumin-bound), reducing renal clearance; and the Aib substitution at position 8, which confers resistance to DPP-4 cleavage [5].

Key pharmacokinetic parameters from the 2024 systematic review [5]:

  • Half-life (SC): 145-168 hours (~1 week)
  • Tmax (SC): 30-56 hours
  • Absolute bioavailability (SC): approximately 89%
  • Clearance: 0.030-0.047 L/h
  • Protein binding: >99% (albumin)
  • Estimated full clearance: approximately 5 half-lives (~35 days)

For the oral formulation, bioavailability is approximately 0.8-1% due to GI proteolytic activity and limited permeation of the intact 31-amino-acid peptide. The SNAC absorption enhancer locally modifies GI permeability near the tablet, enabling this modest but therapeutically sufficient oral absorption [5]. Oral semaglutide must be taken on an empty stomach with no more than 4 oz of water for maximal absorption.

The half-life is consistent across renal and hepatic impairment subgroups — semaglutide does not require dose adjustment for kidney or liver disease based on the pharmacokinetic data reviewed in the 2024 systematic review [5].

Oral Semaglutide Dosing: PIONEER and OASIS-1

Oral semaglutide uses a different dose range than the subcutaneous formulation, reflecting the ~0.8-1% oral bioavailability. PIONEER trials studied three oral doses for type 2 diabetes: 3 mg, 7 mg, and 14 mg once daily [9]. The OASIS-1 weight management trial studied 50 mg oral once daily — the highest oral dose in Phase 3 — and demonstrated 15.1% mean body weight reduction at 68 weeks [10].

The 50 mg oral dose producing ~15% weight loss is comparable to the 2.4 mg SC dose producing ~14.9% (STEP-1), which is consistent with the pharmacokinetic calculation: 50 mg × 0.8-1% bioavailability ≈ 0.4-0.5 mg absorbed systemically, similar in order of magnitude to the 2.4 mg SC formulation's 89% bioavailability [5]. This pharmacokinetic relationship explains why oral semaglutide requires a substantially higher administered dose to achieve equivalent systemic exposure to the SC formulation.

Trial Exclusion Criteria: Who Was Not Studied

Understanding who was excluded from semaglutide trials clarifies the population in whom the evidence applies. Across the STEP and SUSTAIN programs, common exclusions included:

  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN-2) — due to the thyroid C-cell signal in rodent carcinogenicity studies [18]
  • Prior or current pancreatitis
  • Severe renal impairment (eGFR <30) or end-stage renal disease (in some early SUSTAIN trials; subsequent data has been more inclusive)
  • Pregnancy or planning to become pregnant
  • Established significant gastroparesis
  • Prior major GI surgery affecting drug absorption

Exclusion criteria varied by trial — the SELECT trial had different criteria than STEP-1, and PIONEER trials differed again by focusing on T2D populations. The complete criteria are in each trial's published protocol.